Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes

September 9th 2026

340B Under Pressure: Inside Pharma's Push for Greater Clarity

ByMichael Christel,Jesse Mendelsohn

September 9th 2026

HHS Confirms Four Senior FDA Leaders, Including Agency's First-Ever AI Deputy Commissioner

September 9th 2026

How Elevated Cortisol Levels Can Impact Type II Diabetes Treatments

ByMike Hollan,Dr. Elena Christofides

September 9th 2026

IBD's Most Persistent Gap: Q&A with Christian Thienel

ByMike Hollan,Christian Thienel

September 9th 2026

Pharmaceutical Executive Digital Edition - November 2012

Articles in this issue

Related Content

Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes

340B Under Pressure: Inside Pharma's Push for Greater Clarity

HHS Confirms Four Senior FDA Leaders, Including Agency's First-Ever AI Deputy Commissioner

How Elevated Cortisol Levels Can Impact Type II Diabetes Treatments

IBD's Most Persistent Gap: Q&A with Christian Thienel

Trending on PharmExec

Moonwalk Biosciences Closes $70 Million Series B

HHS Confirms Four Senior FDA Leaders, Including Agency's First-Ever AI Deputy Commissioner

How Elevated Cortisol Levels Can Impact Type II Diabetes Treatments

IBD's Most Persistent Gap: Q&A with Christian Thienel

Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes